TABLE 2.
Primers sets used in this study
| Target | Primer set sequence (5′–3′) |
Source or reference | |
|---|---|---|---|
| Forward | Reverse | ||
| qseC | CGCTGAAAGTGCAAACCGAA | CCGCGATAGAGTGAGCAGTT | This study |
| visP | ATGCGTTCAACGATATTGCCG | CGACCGTAGAAAGCGCAAAA | This study |
| fimH | CGGGGTGATGGATTCTCGTT | TCTGGGGATCTCCACCATGT | This study |
| rpoA | GCGCTCATCTTCTTCCGAAT | CGCGGTCGTGGTTATGTG | 22 |
| stx2a | ACCCCACCGGGCAGTT | GGTCAAAACGCGCCTGATA | 21 |
| Universal bacteria, Eub338F/Eub518R | ACTCCTACGGGAGGCAGCAGT | ATTACCGCGGCTGCTGGC | 101 |
| Firmicutes 928F-Firm/1040FirmR | TGAAACTYAAAGGAATTGACG | ACCATGCACCACCTGTC | 102 |
| Bacteroidetes 798cfbF/cfb967R | CRAACAGGATTAGATACCCT | GGTAAGGTTCCTCGCGTAT | 103 |
| Gammaproteobacteria, 1080gF/g1202R | TCGTCAGCTCGTGTYGTGA | CGTAAGGGCCATGATG | 102 |
| qseC-pJP5603 | ATGGTACCCGACGGCAGAATGGTCCTTAA | GAGCTCCCTGAAGGTTATCCAGTGAGTCC | This study |
| qseC-PBAD33 | GCAGAGCTCATGAAATTTACCCAACGTCTTAGTC | GCAGGTACCTTACATCATCACCATCACCACCCAGCTTACCTTCGCCTC | This study |
| M13 | GTAAAACGACGGCCAG | CAGGAAACAGCTATGAC | Invitrogen |